FDA
-
-
-
-
-
-
-
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor
-
-
-
-
-
-
-
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
-
-
-
-
-
-
-
Insulet projects 20% revenue growth through 2028 at investor day
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Insulet Corporation (PODD)
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Raised to $283 at Citi
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Lowered to $250 at BTIG
-
-
-
-
-
-
-
Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency¹)
-
327,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

